6-(4-(1-hydroxyethyl)phenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one | 1428553-97-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 新黄酮类化合物
• 英文名称: 6-(4-(1-hydroxyethyl)phenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one
• 英文别名: 6-[4-(1-Hydroxyethyl)phenyl]-5,7-dimethyl-4-phenylchromen-2-one；6-[4-(1-hydroxyethyl)phenyl]-5,7-dimethyl-4-phenylchromen-2-one
• CAS: 1428553-97-2
• 化学式: C₂₅H₂₂O₃
• 分子量: 370.448
• InChiKey: RMNUOCJSKSTSEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-bromo-5,7-dimethyl-4-phenyl-2H-chromen-2-one 在 sodium tetrahydroborate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 0.75h， 生成 6-(4-(1-hydroxyethyl)phenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32

  摘要：

  In an effort to develop new and potent agents for therapy against tuberculosis, a high-throughput screen was performed against Mycobacterium tuberculosis strain H37Rv. Two 6-aryl-5,7-dimethyl-4-phenylcoumarin compounds 1a and 1b were found with modest activity. A series of coumarin derivatives were synthesized to improve potency and to investigate the structure-activity relationship of the series. Among them, compounds 1o and 2d showed improved activity with IC90 of 2 mu M and 0.5 mu M, respectively. Further optimization provided compound 3b with better physiochemical properties with IC90 0.4 mu M which had activity in a mouse model of infection. The role of the conformation of the 4- and 6-aryl substituents is also described. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.035

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'INFECTIONS MYCOBACTÉRIENNES
  申请人：BROAD INST INC

  公开号：WO2013049567A1

  公开（公告）日：2013-04-04

  The invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof and further relates to the use of a compound of Formula (I) for the treatment of a bacterial infection, in particular, mycobacterial infection. The compounds of the invention can be used for anti-mycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis.

  该发明涉及式（I）的化合物或其药学上可接受的盐、酯或前药，并进一步涉及使用式（I）的化合物治疗细菌感染，特别是分枝杆菌感染。该发明的化合物可用于对临床敏感和耐药分枝杆菌菌株的抗分枝杆菌活性。
• COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
  申请人：Massachusetts General Hospital

  公开号：US20140296232A1

  公开（公告）日：2014-10-02

  The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

  本发明涉及式I的化合物或其药学上可接受的盐、酯或前药：
• Compounds for the treatment of mycobacterial infections
  申请人：The Broad Institute, Inc.

  公开号：US10766872B2

  公开（公告）日：2020-09-08

  The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

  本发明涉及式 I 化合物或其药学上可接受的盐、酯或原药：
• US9416121B2
  申请人：——

  公开号：US9416121B2

  公开（公告）日：2016-08-16
• US9682064B2
  申请人：——

  公开号：US9682064B2

  公开（公告）日：2017-06-20